openPR Logo
Press release

Biosimilar Monoclonal Antibodies Market Analysis by Product Type and Indication Forecast to 2034

07-21-2025 09:20 AM CET | Health & Medicine

Press release from: Insightace Analytic Pvt Ltd.

Biosimilar Monoclonal Antibodies Market

Biosimilar Monoclonal Antibodies Market

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biosimilar Monoclonal Antibodies Market- by Product (Infliximab, Trastuzumab, Rituximab, Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, Denosumab, Eculizumab and Other Pipeline Products), Indication (Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders and Other Indication), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1218

According to the latest research by InsightAce Analytic, the global Biosimilar Monoclonal Antibodies market is valued at USD 7.8 Billion in 2024. It is expected to reach USD 32.1 Billion by the year 2034, with a CAGR of 15.3% during a forecast period of 2025-2034.

The production of monoclonal antibodies (mAbs) involves the utilization of identical immune cell clones derived from a single parent cell. Monoclonal antibodies generated from the same parent cell are termed biosimilar monoclonal antibodies, as they closely resemble the original reference biologic in terms of quality, efficacy, and safety. These biosimilars constitute an important class of biotherapeutic products. Due to their complex biological nature, mAb biosimilars undergo extensive post-translational modifications. They are widely employed in the treatment of various autoimmune, inflammatory, and chronic diseases.

The global biosimilar monoclonal antibody market is driven by factors such as the increasing production of advanced mAbs, the growing elderly population, and the high prevalence of chronic conditions including cancer, kidney failure, rheumatoid arthritis, psoriasis, and diabetes. The expiration of patents on several key monoclonal antibodies is expected to create significant market opportunities in the coming years. Demand for mAbs is projected to accelerate throughout the forecast period, fueled by these patent expirations.

Nevertheless, the market faces challenges including the inherent complexity of biologic drug manufacturing, limited clinical trial experience, stringent regulatory requirements for product approvals, and a lack of comprehensive awareness among manufacturers regarding biosimilar regulatory pathways. These factors may constrain market growth to some extent.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

North America is anticipated to be the major contributor to the Biosimilar Monoclonal Antibodies market over the forecast years. The region's strong growth can be ascribed to increased product approvals, a well-established health care infrastructure, and a favorable reimbursement scenario. In addition, the Asia Pacific regional market is expected to register significant growth during the estimated period because chronic disease burden, the need for affordable therapies, and government funding for healthcare facility improvements are all on the rise.

Major market players operating in the Biosimilar Monoclonal Antibodies market include
BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia), Dr. Reddys Laboratories Ltd (Hyderabad), 3SBio (China), Reliance Life Sciences (India), Hisun Pharma (China), Celgen Biopharma (China), Torrent Pharmaceuticals (Ahmedabad), Cadila Healthcare (Cadila Healthcare), Mylan Inc. (US) and others.

Recent collaborations and agreements in the market:
• In July 2021, Abzena (UK), a global partner research organization for biologics and bioconjugates, and BioXpress Therapeutics (Switzerland) collaborated to support third-party biosimilar development. This collaboration resulted in an integrated solution by two prominent service providers in biosimilar development and GMP manufacturing.
• In February 2021, Mylan (US) introduced Ogivri, a trastuzumab biosimilar. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer, previously sold as Herceptin by Genentech.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1218

Market Segments
Global Biosimilar Monoclonal Antibodies Market, by Product, 2022-2030 (Value US$ Mn)
• Infliximab
• Trastuzumab
• Rituximab
• Adalimumab
• Bevacizumab
• Cetuximab
• Ranibizumab
• Denosumab
• Eculizumab
• Other Pipeline Products
Global Biosimilar Monoclonal Antibodies Market, by Indication, 2022-2030 (Value US$ Mn)
• Oncology
• Inflammatory & Autoimmune Disorders
• Chronic Diseases
• Blood Disorders
• Other Indication
Global Biosimilar Monoclonal Antibodies Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Biosimilar Monoclonal Antibodies market
 To receive an industry overview and future trends of the Biosimilar Monoclonal Antibodies market
 To analyze the Biosimilar Monoclonal Antibodies market drivers and challenges
 To get information on the Biosimilar Monoclonal Antibodies market value (US$ Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Biosimilar Monoclonal Antibodies market industry

Read Overview Report- https://www.insightaceanalytic.com/report/global-biosimilar-monoclonal-antibodies-market/1218

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Monoclonal Antibodies Market Analysis by Product Type and Indication Forecast to 2034 here

News-ID: 4111416 • Views:

More Releases from Insightace Analytic Pvt Ltd.

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market to Grow at 5.3% CAGR Amid Rising Awareness of PCOS and PMS
Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market to Grow at 5 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market- (By Product Type (Combined Nutritional Supplements, Single Nutritional Supplements), By Type Indication (Perimenopause, PMS), By Formulation (Capsules/Tablets, Powder, Softgels, Other), By Sales Channel (Pharmacies/Drug Stores, Online Sales Channel, Direct Sales Channel, Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research
Cell and Gene Therapy CRO Market Forecast Shows Robust Growth Across North America, Europe, and Asia-Pacific
Cell and Gene Therapy CRO Market Forecast Shows Robust Growth Across North Ameri …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell and Gene Therapy CRO Market- (By Type of Cell Therapy (CAR-NK, CAR-T, TCR-T, and Others), By Type of Genetic Modification (Ex vivo and In vivo), By Stage of Development (Discovery, Preclinical, and Clinical)), By Therapeutic Area, By End-user, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by
Bioseparation Systems Market Top Companies Study - GE Healthcare Life Sciences, Pall Corporation, 3M Company, Waters Corporation.
Bioseparation Systems Market Top Companies Study - GE Healthcare Life Sciences, …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Bioseparation Systems Market- (By Type (Centrifugation Technology, Cell Disruption Technology, Chromatography Technique, Extraction Technique, Filtration Technologies and Membrane-based Bioseparation and Precipitation), Application (Food, Life Sciences, Pharmaceutical and Biopharmaceutical)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Bioseparation Systems Market is valued at US$
Medical Nutrition Market Key Players Analysis - Abbott Laboratories; Pfizer Inc.; Bayer AG; Nestle S.A.; GlaxoSmithKline plc.
Medical Nutrition Market Key Players Analysis - Abbott Laboratories; Pfizer Inc. …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Medical Nutrition Market Size, Share & Trends Analysis Report By Nutrition Type (Proteins, Carbohydrates, Multivitamins & Antioxidants, Amino Acids, Fibers, Minerals), By Indication (Diabetes, Cancer, Gastrointestinal Diseases, Metabolic Syndromes), By Patient Type (Infants, Adults, And Geriatric Populations), Indication (Diabetes, Cancer, Gastrointestinal Diseases, Metabolic Syndromes), End-User (Home Care Settings, Long-Term Care Facilities, And Ambulatory Surgical

All 5 Releases


More Releases for Monoclonal

Rising Popularity Of Cost-Efficient Biosimilar Monoclonal Antibodies Fuels Monoc …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Monoclonal Antibodies (MAbs) Market Through 2025? The market for monoclonal antibodies (MAbs) has experienced swift expansion in the recent past. The market value is projected to rise from $234.37 billion in 2024 to $261.66 billion in 2025, exhibiting a compound annual growth
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Arthritis Monoclonal Antibodies Market Report 2024 - Arthritis Monoclonal Antibo …
"The Business Research Company recently released a comprehensive report on the Global Arthritis Monoclonal Antibodies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The arthritis monoclonal antibodies
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Monoclonal Antibody Therapy Market - Empowering the immune system: Monoclonal an …
Newark, New Castle, USA: The "Monoclonal Antibody Therapy Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Monoclonal Antibody Therapy Market: https://www.growthplusreports.com/report/monoclonal-antibody-therapy-market/7736 This latest report researches the industry structure,